WHAT IS CJC-1295

CJC-1295 without DAC is a synthetic peptide analog derived from the first 29 amino acids of the naturally occurring human Growth Hormone-Releasing Hormone (GHRH), also known as GHRH (1-29). It is often referred to by its structure-based name, Modified GRF (1-29).

The original GHRH (1-29) peptide is prone to rapid breakdown in the body. CJC-1295 without DAC includes specific amino acid substitutions at positions 2, 8, 15, and 27. These modifications enhance the peptide's stability and resistance to enzymatic degradation, particularly by the enzyme DPP-IV (dipeptidyl peptidase IV), thereby slightly extending its half-life compared to Sermorelin (the unmodified GHRH 1-29).

WHAT DOES CJC-1295 DO?

Thanks to its abbreviated half-life, CJC-1295 without DAC can be extensively metabolized by an organism, potentially mitigating the adverse reactions. By mimics the action of GHRH, when administered, it binds to the GHRH receptors in the pituitary gland and leads to an increase in the secretion of growth hormone. 

This increased section leads to various physiological benefits, ranging from muscle growth, fat loss, and improved recovery times. It does this by activating the GH axis, which leads to a downstream increase in systemic growth hormone levels. Subsequently, driving the production of Insulin-like Growth Factor(IGF-1) in the liver. Both GH and IGF-1 are essential for tissue repair and metabolic function.

BENEFITS/ CLINICAL TRIALS

While the direct benefit observed from CJC-1295 is the increased production of GH, the extended benefits are widespread. 

Key Benefits observed:

• Body Composition Improvements
  • Enhanced protein synthesis, granted lean muscle development, and increased strength
  • Higher fat metabolism. Particularly visceral fat. 
• Enhanced Recovery & Repair
  • Accelerated recovery from exercise-induced microtrauma, due to increased cellular replication and collagen synthesis. 
  • Supports joint, tendon, and ligament health (caused by increased GH/IGF-1)
• Sleep Quality: 
  • Deeper, more restorative sleep has been observed during Slow Wave Sleep (SWS), where the body's natural high GH pulse occurs. 
• Cognitive Function:
  • In some cases shown to improve mood, mental clarity, and focus.
• Anti-Aging:
  • Thanks to the better collagen turnover in the body, it can potentially lead to better skin elasticity and vitality. 

 Clinical Trial Findings:

CJC-1295 (with DAC version) progressed to Phase 2 trials for growth hormone deficiency but was discontinued (due to an adverse event later deemed unrelated to the drug). The non-DAC form, Modified GRF (1-29), is widely studied in preclinical research and small human trials, often paired with a Growth Hormone Releasing Peptide (GHRP).

SIDE EFFECTS

The non-DAC version is generally considered to have a milder side effect profile than the long-acting DAC form due to its rapid clearance and more natural pulsatile action.

• Nervous System/Systemic:

  • Headache/Dizziness: Often transient, occurring shortly after injection.

  • Flushing/Warmth: A temporary feeling of warmth or flushing across the face/body due to a transient systemic vasodilatory reaction.

  • Nausea/Fatigue: typically mild.

• Local Reactions:

  • Redness, swelling, itching, or pain at the subcutaneous injection site.

• Metabolic Concerns:

  • Potential for elevated blood glucose or increased insulin resistance with chronic, high-dose use, necessitating careful metabolic monitoring.

  • Risk of water retention or temporary joint discomfort, though less pronounced than with direct Human Growth Hormone (HGH) or the DAC variant.

IS CJC-1295 w/o DAC SAFE?

CJC-1295 without DAC is not FDA-approved for human therapeutic use.

While research suggests it is safe and well-tolerated in short-term studies when administered in carefully controlled pulses, its unapproved status means:

1. Long-Term Effects are Unknown: The full impact of chronic use on cardiovascular health, glucose regulation, or promotion of latent malignancies is not fully established via large-scale human trials.

2. Regulatory Prohibition: CJC-1295 (both forms) is on the FDA's list of substances that should not be compounded and is prohibited by the World Anti-Doping Agency (WADA) due to its performance-enhancing properties.

3. Generally Well Tolerated: If supervised by a physician, CJC-1295 w/o DAC has a record of remaining in good standing, particularly in short-term use. 
4. Underlying Conditions: All peptides and drugs that influence growth hormone should be avoided by individuals with active cancer, due to their potential for tumor growth stimulation. It should also be avoided by individuals with uncontrolled diabetes or blood sugar issues. 

DOSAGE

CJC-1295 dosages may vary based on variables like age and weight. A typical starting dose of CJC-1295 and ipamorelin is 0.2mg per injection. Recommended locations are places with subcutaneous fat, including the arm, thigh, and belly. 

• Frequency: requires multiple daily injections (often 1-3 times) due to its shortened half-life. 
• Protocol: It should be combined with additional GHRP peptides like Ipamorlin or GHRP-6 to maximize GH pulse amplitude. 
• Duration: Use for 8-12 weeks followed by a washout period. 

RECONSTITUTION

CJC-1295 without DAC is supplied as a lyophilized (freeze-dried) powder and requires reconstitution before injection.

• Reconstitution Fluid: Use sterile or bacteriostatic water (BAC Water).

• Standard Dilution: For a typical 10 mg vial, adding 1 mL of BAC water results in a concentration of 10 mg/mL, resulting in a highly concentrated solution that can be easily drawn on a U100 syringe (100mcg dose = 10 units)

• Mixing Technique: Inject the BAC Water slowly down the side of the vial. DO NOT SHAKE vigorously. Gently swirl or roll the vial between your hands for several minutes until the powder is completely dissolved into a clear solution.

• Post-Reconstitution Storage: Once reconstituted, the solution must be stored in the refrigerator 2°C to 8°C or 36°F to 46°F and is typically stable for 14 to 28 days.

WHERE TO BUY CJC-1295 w/o DAC

Researchers should always vet their sources to ensure that a few key factors are present in their test subjects. With the rise in peptide popularity in recent years, many companies have created peptides that undergo little to no testing, quality standards, or regulations. As it is not regulated by the FDA, researchers must do their due diligence and look closely at the company's practices and standards. 

When selecting a supplier for CJC-1295 w/o DAC, focus on transparency and quality assurance, not customer testimonials:

1. Quality Documentation: A reputable supplier must provide:
   •  Certificate of Analysis (COA): This document must be recent (corresponding to the batch/lot number purchased) and demonstrate a minimum purity of >95% via High-Performance Liquid Chromatography (HPLC) testing.
   • Mass Spectrometry (MS) Data: The COA must include mass spectrometry (MS) confirmation to verify the compound’s exact molecular weight, confirming its chemical identity.
   • Contaminant Testing: Look for reports on heavy metals, microbial load, and solvent residues (e.g., residual trifluoroacetic acid, or TFA). The presence of these contaminants can severely compromise research and introduce unknown toxicity.
2. Vendor Verification and Transparency 

   • Specialization: Prioritize vendors who specialize in the manufacturing and distribution of peptides for academic and biotechnology research, rather than general supplement vendors.

   • Manufacturing Origin: Inquire about the source of the raw materials and the manufacturing protocols. Ideal suppliers adhere to strict quality control processes.

   • Handling & Storage: The supplier must provide clear documentation on the proper storage and handling procedures for the peptide to maintain its stability and integrity.

Conclusion on Procurement: Given the high risk of contamination, mislabeling, and legal ambiguity. The use of CJC-1295 w/o DAC outside of this defined research context poses unacceptable, unquantified risks to human health.

REFERENCES

• PubChem. "CJC1295 Without DAC | C152H252N44O42 | CID 91976842."

• The European Business Review. "CJC-1295 No DAC and Growth Hormone Pulsatility."

• PubMed (ID 17018654). "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog."

• Yunique Medical. "CJC-1295 Growth Hormone Explained."

• FDA. "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks."

• Innerbody. "CJC-1295 + Ipamorelin | Benefits, Safety & Buying Advice."

• Sciences, BOC. “What Is CJC1295 without DAC?” BOC Sciences, 28 Mar. 2025, www.bocsci.com/resources/what-is-cjc1295-without-dac.html?srsltid=AfmBOoo4y2GCZaSfjvuHmhOh-zZHkyOJytRD2YQaUIQBQaIzxH4MmOFm. 

• “Peptide Therapy - CJC-1295.” Revolution Health & Wellness, revolutionhealth.org/blogs/news/peptide-therapy-cjc-1295#:~:text=Side%20Effects%20and%20Safety%20Profile,Fatigue%20or%20lethargy%20if%20overdosed. Accessed 12 Nov. 2025. 
• Min, Dan. “CJC-1295 + Ipamorelin: Benefits, Safety & Buying Advice [2025].” Innerbody, Innerbody Research, 2 May 2025, www.innerbody.com/cjc-1295-and-ipamorelin.